IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW) today announced updates from
its annual meeting, in which Edwards' stockholders voted with the
board's recommendations on all proxy proposals:
- All eight director nominees were elected as directors of the
company for a one-year term;
- Stockholders advised that they approve the compensation of the
company's named executive officers;
- Stockholders have approved the Amendment and Restatement of the
company's U.S. and International Employee Stock Purchase
Plans;
- Stockholders have ratified the appointment of the company's
independent registered public accounting firm for fiscal year
2021;
- Stockholders have advised that they do not approve the
stockholder proposal regarding action by written consent; and
- Stockholders have advised that they do not approve the
stockholder proposal to adopt a policy to include non-management
employees as prospective director candidates.
During the meeting, the company also announced changes to the
company's board of directors. Nicholas J.
Valeriani, a director since 2014, has been appointed chair
of the compensation and governance committee. William J. Link, Ph.D., who has been a director
since 2009, has retired from the board.
"I'd like to take this opportunity to thank and recognize Bill
for his 12 years of contributions and insight in his service to
Edwards' board," said Michael A.
Mussallem, Edwards' chairman and CEO. "I am grateful to Bill
for his dedication and guidance during an immense period of growth
for Edwards."
The company also announced today that the board of directors
authorized an additional $1 billion
for repurchases of the company's outstanding shares of common stock
under its share repurchase program. As of May 1, 2021, a total of $262 million authorization remains under the
program. This authorization enables the company to repurchase
shares to continue executing its capital allocation strategies. The
company may repurchase shares in the open market or in privately
negotiated transactions. The timing and extent of any repurchase
will depend upon market conditions, corporate requirements and
other factors.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused
innovations for structural heart disease and critical care
monitoring. We are driven by a passion for patients, dedicated to
improving and enhancing lives through partnerships with clinicians
and stakeholders across the global healthcare landscape. For more
information, visit Edwards.com and follow us on Facebook,
Instagram, LinkedIn, Twitter and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, the execution of the
company's capital allocation strategies and timing of
repurchases. Forward-looking statements are based on
estimates and assumptions made by management of the company and are
believed to be reasonable, though they are inherently uncertain and
difficult to predict. Our forward-looking statements speak only as
of the date on which they are made and we do not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of the statement.
Statements of past performance, efforts, or results about which
inferences or assumptions may be made can also be forward-looking
statements and are not indicative of future performance or results;
these statements can be identified by the use of words such as
"continued," "transform," "develop," "preliminary," "initial,"
diligence," "industry-leading," "compliant," "indications," or
"early feedback" or other forms of these words or similar words or
expressions or the negative thereof. Investors are cautioned
not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission including its Annual Report on Form 10-K
for the year ended December 31, 2020
and the Quarterly Report on Form 10-Q for the quarter ended
March 31, 2021. These filings, along
with important safety information about our products, may be found
at edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are
trademarks of Edwards Lifesciences Corporation and its affiliates.
All other trademarks are the property of their respective
owners. This statement is made on behalf of Edwards
Lifesciences Corporation and its subsidiaries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/edwards-announces-updates-from-annual-meeting-301283963.html
SOURCE Edwards Lifesciences Corporation